Alexion Pharmaceuticals (ALXN) Getting Somewhat Positive Media Coverage, Report Shows

Media coverage about Alexion Pharmaceuticals (NASDAQ:ALXN) has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Alexion Pharmaceuticals earned a daily sentiment score of 0.15 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 45.9577049685171 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the headlines that may have impacted Accern Sentiment’s rankings:

Shares of Alexion Pharmaceuticals (NASDAQ ALXN) traded down $0.34 during mid-day trading on Wednesday, reaching $121.46. 1,434,357 shares of the company’s stock were exchanged, compared to its average volume of 2,170,000. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.96 and a quick ratio of 2.51. Alexion Pharmaceuticals has a twelve month low of $96.18 and a twelve month high of $149.34. The company has a market cap of $27,140.00, a P/E ratio of 54.22, a P/E/G ratio of 1.03 and a beta of 1.17.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.32 by $0.12. Alexion Pharmaceuticals had a net margin of 14.57% and a return on equity of 12.55%. The firm had revenue of $859.00 million for the quarter, compared to the consensus estimate of $864.34 million. During the same period last year, the firm earned $1.23 earnings per share. The company’s quarterly revenue was up 7.5% on a year-over-year basis. analysts expect that Alexion Pharmaceuticals will post 4.82 earnings per share for the current fiscal year.

Several analysts have commented on the stock. UBS Group cut shares of Alexion Pharmaceuticals from a “strong-buy” rating to an “outperform” rating in a research note on Thursday, January 4th. Raymond James Financial reiterated an “outperform” rating and issued a $130.00 price target (down previously from $178.00) on shares of Alexion Pharmaceuticals in a research note on Thursday, January 4th. They noted that the move was a valuation call. Leerink Swann reiterated a “buy” rating and issued a $182.00 price target on shares of Alexion Pharmaceuticals in a research note on Monday, September 25th. BMO Capital Markets reiterated an “outperform” rating and issued a $173.00 price target (up previously from $168.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday, September 13th. Finally, SunTrust Banks reiterated a “buy” rating and issued a $180.00 price target (up previously from $170.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday, September 13th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and twenty have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $153.61.

In other news, CEO Ludwig Hantson sold 2,553 shares of the stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $121.63, for a total transaction of $310,521.39. Following the transaction, the chief executive officer now directly owns 36,172 shares in the company, valued at $4,399,600.36. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 4.35% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION WARNING: This article was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.com-unik.info/2018/01/10/alexion-pharmaceuticals-alxn-getting-somewhat-positive-media-coverage-report-shows.html.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Insider Buying and Selling by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit